Faron's BEXMAB: A Promising Immunotherapy for Myeloid Malignancies

Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON) recently presented encouraging data from its BEXMAB study at the 66th American Society of Hematology (ASH) Annual Meeting. The study, an open-label Phase I/II clinical trial, investigates bexmarilimab, a novel anti-Clever-1 humanized antibody, in combination with standard of care (SoC) in patients with aggressive myeloid leukemias. The results indicate that BEXMAB could be a promising immunotherapy for treating myeloid malignancies.

The BEXMAB study has shown remarkable overall response rates (ORR) in both higher-risk frontline and hypomethylating agent (HMA)-failed myelodysplastic syndrome (MDS) patients. In the refractory or relapsed HMA failed MDS patient population (r/r MDS), the ORR was an impressive 80% (16 out of 20), with 70% (14 out of 20) achieving complete response (CR) / marrow complete remission (mCR) / partial response (PR). Additionally, four patients have moved on to receive a bone marrow transplant, and the estimated median overall survival (mOS) in the r/r MDS population is approximately 13.4 months.



The combination of bexmarilimab and azacitidine has been well-tolerated, with immune-related adverse events observed at higher dose levels. Target engagement and expression in the bone marrow, along with an increased antigen presentation capacity and presence of CD8 T and NK cells, support bexmarilimab's mechanism of action.



The BEXMAB study's results suggest that bexmarilimab, in combination with SoC, could significantly improve treatment outcomes for patients with myeloid malignancies. The deep and durable responses observed in r/r MDS patients, along with the well-tolerated combination, have the potential to transform the treatment landscape for these patients. If these results are confirmed in larger, controlled trials, BEXMAB could become a standard of care, improving patient outcomes and reducing healthcare costs.

In conclusion, Faron's BEXMAB study has presented promising data at the ASH Annual Meeting, indicating that bexmarilimab could be a valuable addition to the treatment arsenal for myeloid malignancies. The study's results warrant further investigation and could pave the way for a new standard of care in the field.